Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal LFG316 in non-infectious uveitis requiring systemic immunosuppression
2011-003254-90Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tesidolumab in non-infectious intermediate uveitis, Posterior uveitis (non-infectious) and non-infectious panuveitis (NIU) (2 arms), sponsored by Novartis. Primary endpoint: Primary response rate in LFG316 arm at Day 85. Started Dec 2011; status: completed.
02
Drugs
tesidolumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on 2011-003254-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003254-90.